PHAXIAM Therapeutics (BATS-CHIXE:PHXMP) - Hisse Senedi Fiyatı, Haberler ve Analizler

PHXMP Stoklara Genel Bakış

A biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. Daha fazla detay

PHXMP temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Hisse senetleri oldukça likit değildir

Anlamlı bir piyasa değeri yok ( €17M )

Anlamlı bir geliri yok ( €1M )

+ 1 daha fazla risk

PHAXIAM Therapeutics S.A. Rakipler

ProBiotix Health

OFEX:PBX

UK£10.7m

Verici Dx

AIM:VRCI

UK£8.2m

Genflow Biosciences

LSE:GENF

UK£6.1m

Oncimmune Holdings

AIM:ONC

UK£17.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti PHAXIAM Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	€2.21
52 Haftanın En Yüksek Seviyesi	€0
52 Haftanın En Düşük Seviyesi	€0
Beta	1.86
11 Aylık Değişim	0%
3 Aylık Değişim	n/a
1 Yıllık Değişim	n/a
33 Yıllık Değişim	n/a
5 Yıllık Değişim	-95.62%
Halka arzdan bu yana değişim	-97.85%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	PHXMP	GB Biotechs	GB Pazar
7D	0%	1.5%	2.2%
1Y	n/a	-17.9%	8.8%

Getiri vs. Endüstri: PHXMP un UK Biotechs sektörüne göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Getiri vs Piyasa: PHXMP un UK Piyasasına göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Fiyat Oynaklığı

Is PHXMP's price volatile compared to industry and market?
PHXMP volatility
PHXMP Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: PHXMP son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: PHXMP 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2004	68	Thibaut Fayet	www.phaxiam.com

PHAXIAM Therapeutics S.A. Temel Bilgiler Özeti

PHAXIAM Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
PHXMP temel i̇stati̇sti̇kler
Piyasa değeri	€16.79m
Kazançlar(TTM)	-€23.49m
Gelir(TTM)	€1.33m

12.7x

P/S Oranı

-0.7x

F/K Oranı

PHXMP aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
PHXMP gelir tablosu (TTM)
Gelir	€1.33m
Gelir Maliyeti	€0
Brüt Kâr	€1.33m
Diğer Giderler	€24.81m
Kazançlar	-€23.49m

Son Raporlanan Kazançlar

Dec 31, 2023

Sonraki Kazanç Tarihi

Sep 25, 2024

Hisse başına kazanç (EPS)	-2.35
Brüt Marj	100.00%
Net Kâr Marjı	-1,771.34%
Borç/Özkaynak Oranı	39.8%

PHXMP uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

PHXMP Stoklara Genel Bakış

Risk Analizi

PHAXIAM Therapeutics S.A. Rakipler

OFEX:PBX

UK£10.7m

AIM:VRCI

UK£8.2m

LSE:GENF

UK£6.1m

AIM:ONC

UK£17.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in U.S

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

Recent updates

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in U.S

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

Insufficient new directors

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

Insufficient new directors

No longer forecast to breakeven

No longer forecast to breakeven

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

No longer forecast to breakeven

No longer forecast to breakeven

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2023

Revenue misses expectations

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

PHAXIAM Therapeutics S.A. Temel Bilgiler Özeti

12.7x

-0.7x

Kazanç ve Gelir